Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 216

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin

Eisert, Wolfgang G., Hauel, Norbert, Stangier, Joachim, Wienen, Wolfgang, Clemens, Andreas, van Ryn, Joanne·2010·Arteriosclerosis, Thrombosis, and Vascular Biology

Abstract

Dabigatran is a highly selective, reversible, and potent thrombin inhibitor and is orally available as the prodrug, dabigatran etexilate. It has shown antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action and predictable pharmacodynamic response. Peak plasma concentrations of dabigatran occur 1 to 2 hours after ingestion of the prodrug. The terminal half-life of dabigatran is 12 to 14 hours in elderly volunteers. Dabigatran is not metabolized by cytochrome P450 isoenzymes and does not interact with food. Dabigatran has a low potential for drug-drug interactions and is predominantly renally excreted. Dabigatran etexilate as chronic therapy effectively prevents the recurrence of venous thromboembolism and cardioembolic stroke. For the first time, it has been demonstrated clinically that there may be an effective and safe alternative to warfarin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/atvbaha.110.203604

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Metadata

Authors
Eisert, W. G., Hauel, N., Stangier, J., Wienen, W., Clemens, A., & van Ryn, J.
Venue
Arteriosclerosis, Thrombosis, and Vascular Biology
Published
2010-10
Volume
30
Issue
10
Pages
1885-1889
ISSN
  • 1079-5642 (ISSN-L)
  • 1524-4636
OpenAlex
W2170251955
Cited by
216
References
1
FWCI
15.62
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin. https://app.cochat.ai/papers/10.1161/atvbaha.110.203604
The paper
Eisert, W. G., Hauel, N., Stangier, J., Wienen, W., Clemens, A., & van Ryn, J. (2010). Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.110.203604

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.